Opendata, web and dolomites

VASA SIGNED

Vaccine Against Schistosomiasis for Africa. A Phase I clinical study of the SchistoShield® anti-schistosomiasis vaccine in adults in endemic areas of sub-Saharan Africa

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 VASA project word cloud

Explore the words cloud of the VASA project. It provides you a very rough idea of what is the project "VASA" about.

intestinal    impacting    vaccines    cgmp    innate    forms    schistosomiasis    billion    safety    lasting    project    expression    elimination    transferred    compromised    data    signatures    human    science    hepatic    transfer    prevention    requested    preferred    immune    poverty    faso    schistosoma    chemotherapy    downstream    gene    effectiveness    egg    blocking    adjuvant    regular    countries    schistoshield    species    manufacturing    healthy    infections    baboon    prophylactic    global    request    reg    fecundity    sm    therapeutic    madagascar    resource    people    antigengla    mass    haematobium    refine    burden    causing    74    candidate    p80    disease    se    endemic    site    anti    pathology    programs    urgently    potent    tropical    urinary    vaccine    requiring    adults    immunogenicity    efficacy    consistently    treatment    gmp    african    re    diagnostic    transmission    schistosome    capacity    clinical    burkina    techniques    resolving    protection    adaptive    settings    mansoni    efficacious    epidemiological    ranked    correlates    model    exhibited    reinfection    poor    manufacturer    constraints    antibodies   

Project "VASA" data sheet

The following table provides information about the project.

Coordinator
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE 

Organization address
address: TRINITY LANE THE OLD SCHOOLS
city: CAMBRIDGE
postcode: CB2 1TN
website: www.cam.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 0 €
 EC max contribution 6˙619˙342 € (0%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Two-Stage-RTD
 Funding Scheme RIA-LS
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2024-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) coordinator 1˙537˙385.00
2    INTERNATIONAL VACCINE INSTITUTE KR (Seoul) participant 1˙217˙823.00
3    UNIVERSITY OF ANTANANARIVO MG (Antananarivo) participant 864˙420.00
4    TEXAS TECH UNIVERSITY SYSTEM US (LUBBOCK) participant 704˙831.00
5    GROUPE DE RECHERCHE ACTION EN SANTE SARL BF (OUAGADOUGOU) participant 643˙812.00
6    ACADEMISCH ZIEKENHUIS LEIDEN NL (LEIDEN) participant 612˙856.00
7    PAI LIFE SCIENCES INC. US (WILMINGTON) participant 387˙290.00
8    GOETEBORGS UNIVERSITET SE (GOETEBORG) participant 350˙000.00
9    UNIVERSITE OUAGA I PROFESSEUR JOSEPH KI-ZERBO BF (OUAGADOUGOU 03) participant 259˙672.00
10    EBERHARD KARLS UNIVERSITAET TUEBINGEN DE (TUEBINGEN) participant 41˙250.00

Map

 Project objective

Schistosomiasis is a poverty-related neglected tropical disease, impacting one billion people in 74 countries. Science ranked a schistosomiasis-vaccine as one of the top-10 vaccines urgently needed. Chemotherapy is the preferred method for schistosomiasis control; but the effectiveness of mass-treatment programs is compromised by reinfection requiring regular re-treatment. An efficacious vaccine, with long-lasting protection against all schistosomiasis forms, would impact disease control. We request funding for the clinical development of our SchistoShield®-vaccine (Sm-p80 antigenGLA-SE adjuvant) in Burkina Faso and Madagascar, where Schistosoma mansoni (causing intestinal/hepatic schistosomiasis) and S. haematobium (causing urinary schistosomiasis) are endemic. In baboon studies, SchistoShield® has been effective against all major schistosome species. It is the only vaccine candidate having consistently exhibited potent prophylactic, anti-fecundity, egg-induced pathology resolving, transmission-blocking and therapeutic efficacy. The objectives are to 1) transfer vaccine manufacturing technology for cGMP production to a European manufacturer; 2) assess the safety/immunogenicity of SchistoShield® in a Phase I clinical study in healthy African adults; 3) refine a schistosomiasis human challenge model to identify correlates of protection, innate and adaptive immune signatures, gene expression and the role of antibodies in the prevention/control of Schistosoma infections; and 4) foster a global consortium to advance research on schistosomiasis vaccines and address downstream access constraints in resource-poor settings. The funding requested will allow the clinical development of SchistoShield®. GMP production will be transferred to a European partner. African site research capacity will be improved and epidemiological burden data using novel diagnostic techniques will be used to advance clinical development to Phase 2 and potential future elimination project

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VASA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VASA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

ISLET (2020)

Advancing Innovative Stem Cell-based Therapy for Diabetes in Europe

Read More  

VANGUARD (2020)

New Generation Cell Therapy: Bioartificial Pancreas to Cure Type 1 Diabetes

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More